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Abstract Uromodulin is the most abundant protein in the urine. It is exclusively produced by
renal epithelial cells and it plays key roles in kidney function and disease. Uromodulin mainly exerts
its function as an extracellular matrix whose assembly depends on a conserved, specific proteolytic
cleavage leading to conformational activation of a Zona Pellucida (ZP) polymerisation domain.
Through a comprehensive approach, including extensive characterisation of uromodulin processing
in cellular models and in specific knock-out mice, we demonstrate that the membrane-bound serine
protease hepsin is the enzyme responsible for the physiological cleavage of uromodulin. Our
findings define a key aspect of uromodulin biology and identify the first in vivo substrate of hepsin.
The identification of hepsin as the first protease involved in the release of a ZP domain protein is
likely relevant for other members of this protein family, including several extracellular proteins, as
egg coat proteins and inner ear tectorins.
DOI: 10.7554/eLife.08887.001
Introduction
Uromodulin, also known as Tamm-Horsfall protein, is a 105 kDa glycoprotein exclusively expressed
in the kidney by epithelial cells lining the thick ascending limb (TAL) of Henle’s loop. It is a glycosyl-
phosphatidylinositol (GPI)-anchored protein mainly localised at the apical plasma membrane of TAL
epithelial cells. Uromodulin is secreted into the renal tubule through a conserved proteolytic cleav-
age (Santambrogio et al., 2008). In the urine it constitutes the most abundant protein under physio-
logical conditions (Serafini-Cessi et al., 2003) and it is mainly found as high molecular-weight
polymers. Uromodulin polymerisation is mediated by its Zona Pellucida (ZP) domain, a module pres-
ent in several proteins that assemble into extracellular polymers, such as components of the egg
coat (including sperm receptors ZP3 and ZP2) and of the inner ear tectorial membrane
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(Jovine et al., 2005). Specific cleavage is necessary for protein assembly into polymers, as it releases
an inhibitory hydrophobic motif (external hydrophobic patch, EHP) distal to the ZP domain that pre-
vents polymerisation (Jovine et al., 2004; Schaeffer et al., 2009; Han et al., 2010).
The biological function of uromodulin is complex and only partly understood. Studies in Umod-/-
mice demonstrated that it protects against urinary tract infections (Bates et al., 2004) and renal
stone formation (Liu et al., 2010). Uromodulin has also been shown to modulate the activity of
innate immunity cells via Toll-like receptor 4 signalling (Sa¨emann et al., 2005) or via activation of the
inflammasome (Darisipudi et al., 2012) and to regulate granulopoiesis and systemic neutrophil
homeostasis (Micanovic et al., 2015). Finally, it is involved in the regulation of NaCl transport in the
TAL, based on its role in promoting surface expression of the renal outer medullary potassium chan-
nel (ROMK2) (Renigunta et al., 2011) and of the sodium-potassium-chloride co-transporter (NKCC2)
(Mutig et al., 2011).
Recent data showed that uromodulin plays an important role in chronic diseases of the kidney
(Rampoldi et al., 2011). Mutations in the uromodulin gene (UMOD) cause an autosomal dominant
tubulo-interstitial kidney disease (Hart, 2002). In addition, genome-wide association studies demon-
strated that common variants in the UMOD gene are associated with increased risk for chronic kid-
ney disease (CKD) and hypertension (Ko¨ttgen et al., 2009; Padmanabhan et al., 2010). Such an
effect is due to higher UMOD expression driven by the presence of risk alleles in its gene promoter
(Trudu et al., 2013).
Given the importance of polymerisation for uromodulin activity and the fact that this process
depends on a specific protein cleavage, in this work we aimed at identifying the protease responsi-
ble for such cleavage and urinary secretion.
eLife digest Several proteins in humans and other animals contain a region called a ’zona
pellucida domain’. This domain enables these proteins to associate with each other and form long
filaments. Uromodulin is one such protein that was first identified more than fifty years ago. This
protein is known to play a role in human diseases such as hypertension and kidney failure, but
uromodulin’s biological purpose still remains elusive.
Uromodulin is only made in the kidney and it is the most abundant protein in the urine of healthy
individuals. Uromodulin also contains a so-called ’external hydrophobic patch’ that must be removed
before the zona pellucida domain can start to form filaments. This hydrophobic patch is removed
when uromodulin is cut by an unknown enzyme; this cutting releases the rest of the uromodulin
protein from the surface of the cells that line the kidney into the urine.
Brunati et al. have now tested a panel of candidate enzymes and identified that one called hepsin
is able to cut uromodulin. Hepsin is embedded in the cell membrane of the cells that line the kidney.
When the level of hepsin was artificially reduced in cells grown in the laboratory, uromodulin
remained anchored to the cell surface, its processing was altered and it did not form filaments.
Brunati et al. next analysed mice in which the gene encoding hepsin had been deleted. While
these animals did not have any major defects in their internal organs, they had much lower levels of
uromodulin in their urine. Furthermore, this residual urinary protein was not cut properly and it did
not assemble into filaments. Thus, these findings reveal that hepsin is the enzyme that is responsible
for releasing uromodulin in the urine. This discovery could be exploited to alter the levels of
uromodulin release, and further studies using mice lacking hepsin may also help to understand
uromodulin’s biological role. Finally, it will be important to understand if hepsin, or a similar enzyme,
is also responsible for the release of other proteins containing the zona pellucida domain.
DOI: 10.7554/eLife.08887.002
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Results
Uromodulin cleavage and polymerisation in MDCK cells is mediated by
a serine protease
As for other ZP proteins, uromodulin cleavage at a specific site in the protein C-terminus releases
the interaction between two hydrophobic motifs (internal hydrophobic patch, IHP; external hydro-
phobic patch, EHP) (Figure 1A), leading to conformational activation of the ZP domain and protein
polymerisation (Jovine et al., 2004; Schaeffer et al., 2009; Han et al., 2010).
To understand the nature of such cleavage, we took advantage of a cellular system, Madin-Darby
Canine Kidney (MDCK) cells, where transfected human uromodulin assembles extracellularly in fila-
mentous polymers (Figure 1B,C) that are indistinguishable from the urinary ones (Jovine et al.,
2002). In these cells, uromodulin is secreted as two isoforms that can be separated on gel electro-
phoresis after enzymatic removal of protein N-glycans at about 72 and 77 kDa (Figure 1D). Only the
Figure 1. MDCK cells as a model to study physiological uromodulin shedding. (A) Schematic representation of human uromodulin domain structure
containing a leader peptide (predicted to be cleaved at residue 23), three EGF-like domains, a central domain with 8 conserved cysteines (D8C), a
bipartite Zona Pellucida (ZP) domain (ZP-N/ZP-C) and a glycosylphosphatidylinositol (GPI)-anchoring site (predicted at position 614). Internal (IHP) and
External (EHP) Hydrophobic Patches (Jovine et al., 2004; Schaeffer et al., 2009), Consensus Cleavage Site (CCS) and seven N-glycosylation sites (Y)
are also indicated. (B) Immunofluorescence analysis of non-permeabilised MDCK cells expressing uromodulin. Polymers formed by the protein are
clearly detected on the cell surface. Scale bar, 50 mm. (C) Electron microscopy analysis of uromodulin polymers purified from the medium of MDCK
cells. The arrows indicate the typical protrusions of uromodulin filaments spaced about 130 A˚. Scale bar, 100 nm. (D) Representative Western blot
analysis of N-deglycosylated uromodulin secreted by transfected MDCK cells or purified from urine. A single isoform is clearly seen in the urinary
sample. An isoform with similar molecular weight is released by MDCK cells (white arrowhead), which also secrete a longer and more abundant one
(black arrowhead). (E) Representative tandem mass-spectrometry (MS/MS) spectrum confirming the identity of the C-terminal peptide
572DTMNEKCKPTCSGTRF587 of the short uromodulin isoform released by MDCK cells and table of fragmented ions. The C-terminal residue F587 is
identical to the one that we mapped in human urinary protein (Santambrogio et al., 2008).
DOI: 10.7554/eLife.08887.003
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shorter isoform assembles into polymers, since it is generated by a cleavage that releases the inhibi-
tory EHP motif, while the longer one is generated by a more distal cleavage and still retains the
EHP (Schaeffer et al., 2009). The short uromodulin isoform released by MDCK cells corresponds to
the one found in the urine, as it shares the same molecular weight (Figure 1D) and the same C-ter-
minal residue (F587 [Santambrogio et al., 2008]) (Figure 1E), demonstrating that uromodulin
undergoes physiological cleavage in these cells.
As mapping of the C-terminus of the short uromodulin isoform suggests proteolytic cleavage, we
first treated uromodulin-expressing MDCK cells with a protease inhibitor cocktail (PIC). This treat-
ment led to significant reduction of uromodulin polymerisation on the surface of the cells
(Figure 2A) that is not due to any alteration of protein expression or intracellular distribution (Fig-
ure 2—figure supplement 1), confirming that the polymerisation-competent uromodulin isoform is
generated through the action of a protease. We then treated MDCK cells with the single PIC compo-
nents, each targeting a specific catalytic type of protease, and observed that only inhibitors of serine
proteases significantly reduced uromodulin polymerisation (Figure 2A). Consistently, the expression
of the Kunitz-type serine protease inhibitor Hepatocyte growth factor Activator Inhibitor-1 (HAI-1)
(Shimomura et al., 1997) essentially abolished uromodulin polymerisation on the surface of MDCK
cells and reduced the secretion of the shorter uromodulin isoform (Figure 2—figure supplement 2).
To explore the role of membrane-association for uromodulin cleavage, we expressed a soluble iso-
form of uromodulin, generated by truncation at the GPI-anchoring site (S614X), that is efficiently traf-
ficked and secreted in MDCK cells (Schaeffer et al., 2009). Interestingly, this isoform was neither
processed to the shorter variant nor it formed polymers (Figure 2B,C), indicating that, as in the case
of ZP3 (Jovine et al., 2002), membrane association is necessary to allow uromodulin physiological
cleavage and polymerisation. From these results we conclude that physiological cleavage of uromo-
dulin depends on a serine protease, and that this enzyme is likely membrane associated.
Identification of hepsin as the protease cleaving uromodulin in vitro
We moved further starting from the interesting observation that uromodulin expressed in a different
kidney-derived cell line, Human Embryonic Kidney 293 (HEK293), did not form polymers on the cell
surface (Figure 3A). Accordingly, only the longer polymerisation-incompetent uromodulin isoform
was released by these cells (Figure 3B). We hypothesised that this was due to lack of expression of
the proper serine protease responsible for physiological uromodulin cleavage. Under this assump-
tion, we compared the expression profiles available in Gene Expression Omnibus of known serine
proteases (about 220 enzymes) between MDCK and HEK293 cells, to identify those exclusively
expressed by the former. Among the resulting 23 candidates we then selected only membrane-
bound enzymes that were found to be expressed in available TAL segment transcriptomes
(Yu et al., 2009; Cheval et al., 2011). This strategy led to the identification of only four candidate
enzymes: prostasin (Prss8), hepsin/TMPRSS1 (Hpn), mucin 1 (Muc1) and dipeptidyl-peptidase IV
(Dpp4) (Figure 3C). The last two enzymes were excluded on the basis of their catalytic activity:
Dpp4 sequentially removes N-terminal dipeptides from polypeptides, cleaving after a proline resi-
due (Mentlein, 1999), whereas Muc1 contains a self-cleaving module rather than a classical pepti-
dase S1 domain (Levitin et al., 2005). Validation of transcriptome data confirmed differential
expression of the two candidate proteases, hepsin and prostasin, in MDCK and HEK293 cells (Fig-
ure 3—figure supplement 1A). Interestingly, both proteases are inhibited by the Kunitz-type serine
protease inhibitor HAI-1 (Fan et al., 2005; Herter et al., 2005), in line with our results in MDCK cells
(Figure 2—figure supplement 2).
We validated our hypothesis by expressing either hepsin or prostasin in HEK293 cells. This
induced short cleavage as well as polymerisation of uromodulin, an effect that was dependent on
the catalytic activity of the enzymes, as it was abolished when catalytically inactive isoforms of the
proteases were expressed (Figure 3D,E; Figure 3—figure supplement 1B). Moreover, this effect is
likely direct, as both enzymes could be specifically co-immunoprecipitated with uromodulin from the
lysates of HEK293 cells (Figure 3F). Based on this observation, we assessed whether uromodulin can
be directly cleaved by hepsin and prostasin in vitro. To do so, we carried out cleavage assays by
employing a truncated recombinant form of uromodulin that corresponds to the elastase-resistant
fragment of uromodulin from human urine (efUmod, lacking residues 27–294) (Jovine et al., 2002).
We focussed on this fragment as it primarily consists of the ZP polymerisation domain (Figure 4A).
Also, deletion of the N-terminal part of uromodulin greatly improved its purification efficiency (data
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Figure 2. A serine protease is responsible for the release of polymerisation-competent uromodulin. (A) Immunofluorescence analysis showing
uromodulin on the surface of MDCK cells treated with vehicle (DMSO) (ctr), protease inhibitor cocktail (PIC) or single PIC components, as indicated.
Scale bar, 50 mm. Quantification of the average surface of uromodulin polymers shows that only treatment with PIC or with specific serine protease
inhibitors (AEBSF, aprotinin and leupeptin) significantly reduces uromodulin polymerisation on the surface of MDCK cells. Bars indicate average ± s.e.m.
***p<0.001 (Mann-Whitney test). The graph represents mean ratios of 3 independent experiments (Figure 2—source data 1). (B) Immunofluorescence
analysis of permeabilised (left) or non-permeabilised (right) MDCK cells expressing soluble uromodulin mutant S614X. Uromodulin polymerisation is
abolished by preventing its association to the membrane. Scale bar, 50 mm. (C) Representative Western blot analysis of N-deglycosylated uromodulin
secreted by MDCK cells expressing wild-type or soluble (S614X) uromodulin. Lack of plasma membrane anchoring does not affect uromodulin secretion
but it abolishes its cleavage at the physiological site (white arrowhead).
DOI: 10.7554/eLife.08887.004
The following source data and figure supplements are available for figure 2:
Source data 1. Quantification of the area of uromodulin polymers on the surface of MDCK cells after protease inhibitor treatment (Figure 2A).
DOI: 10.7554/eLife.08887.005
Source data 2. Short cleavage inhibition by HAI-1 expression (Figure 2—figure supplement 2C).
DOI: 10.7554/eLife.08887.006
Figure supplement 1. PIC treatment does not affect uromodulin intracellular distribution and expression.
DOI: 10.7554/eLife.08887.007
Figure supplement 2. Expression of the serine protease inhibitor HAI-1 effectively reduces uromodulin cleavage at the urinary site.
DOI: 10.7554/eLife.08887.008
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Figure 3. Hepsin and prostasin interact with uromodulin to induce its cleavage and polymerisation. (A) Immunofluorescence analysis (extended focus
image) showing uromodulin on the surface of HEK293 cells. The protein is not assembled into polymers when expressed in this cellular system. Scale
bar, 21 mm. (B) Representative Western blot analysis of N-deglycosylated uromodulin secreted by MDCK and HEK293 cells. HEK293 cells only secrete
the longer polymerisation-incompetent uromodulin isoform (black arrowhead), while MDCK cells also secrete the shorter one (white arrowhead). (C)
Schematic representation of the selection process employed to identify candidate enzymes for the secretion of the short uromodulin isoform. Only
membrane-bound serine proteases specifically expressed by MDCK cells and by the TAL segment of the nephron, but not by HEK293 cells, were
selected. (D) Representative Western blot analysis of N-deglycosylated uromodulin secreted by HEK293 cells expressing wild-type or catalytically
inactive human hepsin or prostasin, as indicated. Only wild-type proteases promote the secretion of the short uromodulin isoform by these cells (white
arrowhead). (E) Immunofluorescence analysis (extended focus image) showing uromodulin on the surface of HEK293 cells expressing wild-type or
catalytically inactive hepsin or prostasin, as indicated. Uromodulin polymerisation is induced only when wild-type proteases are expressed. Scale bar, 21
mm. (F) Representative Western blot analysis of uromodulin immunoprecipitation (upper panels) from lysates of HEK293 cells expressing hepsin or
prostasin, as indicated. Both enzymes are co-immunoprecipitated when uromodulin is co-expressed in HEK293 cells (lower panels). The arrowheads
point at hepsin and prostasin specific bands.
DOI: 10.7554/eLife.08887.009
The following figure supplement is available for figure 3:
Figure 3 continued on next page
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not shown), probably because it lacks several N-glycosylation sites. Importantly, this isoform under-
goes proper proteolytic cleavage and forms polymers in MDCK cells (Figure 4B). When incubated
with purified efUmod, both hepsin and prostasin induced a mass shift of efUmod as well as loss of
its C-terminal histidine tag (Figure 4C). These effects were abolished by mutagenesis of the consen-
sus cleavage site (efUmod YAla, carrying the mutation 586RFRS589 > 586AYAA589). Taken together,
these findings indicate that hepsin and prostasin physically interact with uromodulin and cleave it at
the physiological site. Interestingly, hepsin was more efficient than prostasin, since it completely
digested the substrate despite being used at lower concentration (see figure legend).
The two candidate proteases could not be discriminated on the basis of their subcellular localisa-
tion in MDCK cells. Indeed, while endogenous proteases could not be detected, possibly because of
low expression levels or low affinity for the employed antibodies (which were raised against their
human counterparts), transfected hepsin and prostasin both co-localised with uromodulin on the api-
cal membrane of polarised MDCK cells (Figure 5A). Hence, we designed short hairpin RNAs
(shRNAs) to specifically silence either protease in this cellular system. We successfully obtained com-
parable expression knock-down for both enzymes (Figure 5B), but only hepsin silencing led to a sig-
nificant reduction of uromodulin polymerisation on the cell surface (Figure 5C). These results
demonstrate that hepsin is the enzyme responsible for uromodulin cleavage at the urinary site in
MDCK cells.
Hepsin mediates physiological cleavage and polymerisation of
uromodulin in vivo
To understand the physiological relevance of our findings, we then investigated the expression of
endogenous hepsin in mouse kidneys. Remarkably, by microdissecting mouse nephron segments,
we detected strong hepsin expression in the TAL (Figure 6A). Moreover, hepsin co-localises with
uromodulin on the apical membrane of TAL epithelial cells, suggesting a functional interaction
between the two proteins (Figure 6B). To assess the role of hepsin in uromodulin processing in vivo,
we characterised uromodulin urinary secretion in a previously generated Hpn-/- mouse model, which
does not show any gross phenotype or structural abnormality in major organs (Wu et al., 1998).
Notably, urinary uromodulin levels were significantly reduced in Hpn-/- mice (Figure 6C). This was
accompanied by marked accumulation of the mature, fully glycosylated form of uromodulin in kidney
lysates (Figure 6D). On the other hand, no difference was observed in the cellular distribution of
uromodulin in TAL cells, showing typical apical membrane enrichment (Figure 6E), and no change in
Umod gene expression was detected (Figure 6F). These data exclude that reduced levels of urinary
uromodulin in Hpn-/- mice could be due to changes in protein expression or transport to the apical
plasma membrane, strongly suggesting defective protein secretion.
After deglycosylation, urinary uromodulin from Hpn-/- mice appeared as two isoforms: a short
one, with similar electrophoretic mobility as in wild-type urines, and a longer one, normally undetect-
able in urines from wild-type mice (Figure 7A). Mass-spectrometry analysis on the short isoform
showed that it lacks the physiological C-terminus (F588) and is produced by a more distal cleavage
occurring after residue R607 (Figure 7B–D). The same analysis on the long isoform revealed an even
more distal C-terminus, after residue K616 (Figure 7—figure supplement 1), consistent with its
slower electrophoretic mobility. These data demonstrate that absence of hepsin abolishes uromodu-
lin cleavage at the physiological site and induces its misprocessing. Interestingly, uromodulin from
Hpn-/- urines was not sedimented in the pellet fraction of a biochemical polymerisation assay
(Jovine et al., 2002) (Figure 7E), indicating that the residual urinary protein is not assembled into
polymers. This is consistent with the observation that both urinary isoforms in Hpn-/- mice are mis-
processed and still retain the polymerisation-inhibiting EHP motif (Figure 7D) (Jovine et al., 2004;
Schaeffer et al., 2009).
A role for hepsin in the activation of prostasin, whose zymogen is unable to auto-activate, was
demonstrated in vitro (Chen et al., 2010). To assess whether the results observed in Hpn-/- mice
could be due to the lack of hepsin-mediated activation of prostasin, we first investigated the
Figure 3 continued
Figure supplement 1. Hepsin and prostasin expression in MDCK and HEK293 cells.
DOI: 10.7554/eLife.08887.010
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Figure 4. Hepsin and prostasin directly cleave uromodulin in vitro. (A) Schematic representation of human uromodulin domain structure as shown in
Figure 1A. The region not included in recombinant efUmod is shadowed. (B) The deletion of the elastase-sensitive fragment of uromodulin does not
affect protein polymerisation on the surface of MDCK cells, as shown by immunofluorescence analysis (efUmod wt). As for full-length uromodulin
(Schaeffer et al., 2009), this process depends on correct protein cleavage at the physiological site, since it is abolished when the consensus cleavage
site is mutated (efUmod 4Ala, carrying the mutation 586RFRS589 > 586AAAA589). Scale bar, 50 mm. (C) Purified efUmod, either wild-type (efUmod wt) or
mutated at the consensus cleavage site (efUmod YAla, carrying the mutation 586RFRS589 > 586AYAA589), was incubated with recombinant prostasin or
hepsin, as indicated. Both proteases decrease the mass of wild-type efUmod (white arrowheads in upper and middle panels) and cause the loss of its
C-terminal His-tag (lower panel). Hepsin is more efficient than prostasin, as it drives complete digestion of the product, despite being used at 20x lower
concentration (picomolar ratio between protease and efUmod was 1:100 for hepsin and 1:5 for prostasin, see lanes 7 and 8 for comparison). The
asterisk indicates His-tagged prostasin.
DOI: 10.7554/eLife.08887.011
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expression pattern of endogenous prostasin in mouse kidneys. Confirming data from available tran-
scriptomes, we detected weak prostasin expression in TAL segments where it co-localises with uro-
modulin on the apical plasma membrane of epithelial cells (Figure 7—figure supplement 2A,B). We
Figure 5. Hepsin is the protease mediating uromodulin polymerisation in MDCK cells. (A) Confocal immunofluorescence analysis showing uromodulin
(green), hepsin or prostasin (red) and E-cadherin (blue) (basolateral membrane marker) in polarised MDCK cells, as indicated. Upper panels represent
the reconstruction on the xz axis of merged xy scans, for which a representative image is shown in lower panels. Both serine proteases co-localise with
uromodulin on the apical plasma membrane of polarised MDCK cells. z stacks = 0.3 mm. A: apical, BL: basolateral. Scale bars, 5 mm. (B) Transcript levels
of HPN and PRSS8, as assessed by Real-Time qPCR in MDCK cells transfected with shRNA vectors, as indicated. Expression values (normalised to
glyceraldehyde-3-phosphate dehydrogenase, GAPDH) are shown as relative to cells transfected with control vector. Expression of the proteases is
specifically reduced in silenced cells. Bars indicate average ± s.e.m. **p<0.01, ***p<0.001 (Student’s t test). The graph represents mean ratios of 3
independent experiments (Figure 5—source data 1). (C) Immunofluorescence analysis showing uromodulin on the surface of MDCK cells transfected
with control vector or with shRNA vectors targeting hepsin or prostasin, as indicated. Scale bar, 50 mm. Quantification of the average surface of
uromodulin polymers shows that silencing of hepsin, but not of prostastin, substantially reduces uromodulin polymerisation on the membrane of MDCK
cells. Bars indicate average ± s.e.m. ***p<0.001 (Mann-Whitney test). The graph represents mean ratios of 3 independent experiments (Figure 5—
source data 2).
DOI: 10.7554/eLife.08887.012
The following source data is available for figure 5:
Source data 1. Transcript level of HPN and PRSS8 in MDCK cells after shRNA transfection (Figure 5B).
DOI: 10.7554/eLife.08887.013
Source data 2. Quantification of the area of uromodulin polymers on the surface of MDCK cells after shRNA transfection (Figure 5C).
DOI: 10.7554/eLife.08887.014
Brunati et al. eLife 2015;4:e08887. DOI: 10.7554/eLife.08887 9 of 23
Research article Biochemistry Cell biology
then generated an adult nephron-specific Prss8-/- mouse model and analysed urinary uromodulin.
Secretion of urinary uromodulin in these mice was comparable to controls (Figure 7—figure supple-
ment 2C,D). Moreover, mass-spectrometry analysis on the urinary protein confirmed that it shares
the same C-terminal residue of control animals (Figure 7—figure supplement 2E,F), excluding a
role for prostasin in uromodulin processing in vivo.
Figure 6. Defective uromodulin urinary secretion in mice lacking hepsin. (A) Transcript level of Hpn, as assessed by Real-Time qPCR on microdissected
nephron segments (normalised to Gapdh). Expression of Hpn is detected in proximal straight tubules (PST), thick ascending limb (TAL), proximal
convoluted tubules (PCT), distal convoluted tubules (DCT) and, to a lesser extent, in collecting ducts (CD). Minimal expression of the protease is
detected in glomeruli (GI). Bars indicate average ± s.e.m. of 3 independent experiments (Figure 6—source data 1). (B) Immunofluorescence analysis of
mouse kidney sections showing co-localisation of endogenous hepsin and uromodulin on the apical plasma membrane of TAL epithelial cells. Scale
bar, 20 mm. (C) Representative Western blot analysis of urinary uromodulin secretion in Hpn-/- mice or control animals. Urinary protein loading was
normalised to urinary creatinine concentration. Densitometric analysis shows reduced uromodulin urinary secretion in animals lacking hepsin (average ±
s.d., n = 10/group, Figure 6—source data 2). ***p<0.001 (Student’s t test). (D) Western blot analysis of uromodulin in kidney lysates of Hpn-/- mice or
control animals. Beta-actin is shown as a loading control. Densitometric analysis shows accumulation of uromodulin in kidney lysates from Hpn-/-
mice (average ± s.d., n = 3/group, Figure 6—source data 3). **p<0.01 (Student’s t test). (E) Representative immunofluorescence analysis showing
apical plasma membrane signal of uromodulin in kidney sections from Hpn-/- mice or control animals. Scale bar, 50 mm. (F) Transcript level of Umod, as
assessed by Real-Time qPCR on total kidney extracts from Hpn-/- mice or control animals (normalised to Hprt1). Expression of Umod is comparable
between the two groups of animals (n = 3/group, Figure 6—source data 4). Bars indicate average ± s.e.m. (Student’s t test).
DOI: 10.7554/eLife.08887.015
The following source data is available for figure 6:
Source data 1. Transcript level of Hpn in mouse microdissected nephron segments (Figure 6A).
DOI: 10.7554/eLife.08887.016
Source data 2. Quantification of urinary uromodulin secretion in Hpn-/- and control mice (Figure 6C).
DOI: 10.7554/eLife.08887.017
Source data 3. Quantification of uromodulin levels in kidney lysates of Hpn-/- and control mice (Figure 6D).
DOI: 10.7554/eLife.08887.018
Source data 4. Transcript levels of Umod in Hpn-/- and control mice (Figure 6F).
DOI: 10.7554/eLife.08887.019
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Discussion
Collectively, our results identify hepsin as the enzyme responsible for the physiological release of
uromodulin in the urine. Hepsin, or TMPRSS1, is a member of type II transmembrane serine pro-
teases. It is expressed in several tissues and it has been previously implicated in the processing of
different substrates; however, the physiological relevance of most of these observations remains to
be established (Chen et al., 2010; Hsu et al., 2012; Khandekar and Jagadeeswaran, 2014;
Figure 7. Absence of hepsin in vivo abolishes physiological cleavage and polymerisation of uromodulin. (A) Representative Western blot analysis of N-
deglycosylated urinary uromodulin secreted by Hpn-/- mice or control animals. Hpn-/- mice show the presence of two uromodulin isoforms: a short one
with similar electrophoretic mobility as in wild-type urines (white arrowhead), and a longer one that is absent in samples from wild-type mice (black
arrowhead) (n = 6/group). (B) Mass spectrometry (MS) sequence coverage (52% over the entire protein) of trypsin-digested mouse uromodulin (short
isoform) (UniProt accession Q91X17) purified from urine of Hpn-/- mice. Matching peptides are shown in red, while the C-terminal peptide is shown in
blue. This peptide ends at R607, a distal C-terminal residue with respect to the one reported for mouse urinary uromodulin (F588 [Santambrogio et al.,
2008]). (C) Representative tandem mass-spectrometry (MS/MS) spectrum, confirming the identity of the identified C-terminal peptide
(599VLNLGPITR607) of the short uromodulin isoform released by Hpn-/- mice, and table of fragmented ions. (D) Schematic representation of mouse
uromodulin domain structure as in Figure 1A. The blow-up shows that in the absence of hepsin, the cleavage generating the short uromodulin isoform
is abolished and alternative ones at more C-terminal sites (distal to R607) take place. (E) Representative Western blot analysis of uromodulin in
supernatant (SN) and pellet (P) fractions from a polymerisation assay performed on urinary samples from Hpn-/- mice or control animals. Urinary
uromodulin from control animals is precipitated in the pellet fraction, reflecting full engagement in polymeric structures, while the one from Hpn-/- mice
is only detected in the supernatant (n = 4/group).
DOI: 10.7554/eLife.08887.020
The following source data and figure supplements are available for figure 7:
Source data 1. Transcript level of Prss8 in mouse microdissected nephron segments (Figure 7—figure supplement 2A).
DOI: 10.7554/eLife.08887.021
Source data 2. Quantification of urinary uromodulin secretion in Prss8-/- and control mice (Figure 7—figure supplement 2C).
DOI: 10.7554/eLife.08887.022
Figure supplement 1. Urinary uromodulin misprocessing in Hpn-/- mice.
DOI: 10.7554/eLife.08887.023
Figure supplement 2. Uromodulin secretion is not affected by lack of prostasin in vivo.
DOI: 10.7554/eLife.08887.024
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Ganesan et al., 2011). By identifying hepsin as the enzyme responsible for the release of uromodulin
in the renal tubule, our results reveal an important biological function of this type II transmembrane
serine protease in the renal epithelium. At the same time, they represent a major advancement in
understanding the biology of uromodulin, opening new avenues of research on the regulation and
possibly modulation of its secretion. This could have impact for diseases such as urolithiasis where
the urinary levels of uromodulin may be directly correlated with its protective function. Also, it might
be relevant for CKD and hypertension where we demonstrated that UMOD risk variants are associ-
ated with increased uromodulin expression and urinary levels (Trudu et al., 2013; Olden et al.,
2014). Lack of hepsin does not affect baseline renal function of Hpn-/- mice (serum creatinine: wild-
type 0.78 +/- 0.04 vs Hpn-/- 0.74 +/- 0.14 mg/dL, n = 5/group, p=0.59; blood urea nitrogen: wild-
type 21.6 +/- 3.29 vs Hpn-/- 20.8 +/- 4.12 mg/dL, n= 5/group, p=0.76). In this light, further studies in
Hpn-/- mice with altered uromodulin processing and secretion are warranted to investigate if the
mice develop a phenotype upon additional challenges. The results may provide new insight into uro-
modulin cellular and extracellular functions.
It is well recognised that proteolysis plays a central role in uromodulin polymerisation. This step
leads to the release of an inhibitory intramolecular interaction that prevents premature protein poly-
merisation (Jovine et al., 2004; Schaeffer et al., 2009; Han et al., 2010). Considering the matura-
tion steps of uromodulin along the secretory compartment, hepsin-mediated cleavage likely takes
place at the plasma membrane where the two proteins co-localise, allowing the protein to traffic
within the cell in a polymerisation-incompetent conformation, and to polymerise only once it is
secreted (Figure 8). Interestingly, the C-terminus of human and mouse urinary uromodulin has been
mapped to a phenylalanine residue (F587 and F588, respectively) (Santambrogio et al., 2008). Since
in vitro studies showed that hepsin preferentially cleaves substrates after basic amino acids
(Herter et al., 2005; Be´liveau et al., 2009; Owen et al., 2010), this could result from cleavage at
the following arginine residue and subsequent C-terminal trimming. Post-cleavage trimming by car-
boxypeptidases is not uncommon and it has already been proposed for several secreted proteins,
including urokinase (Gu¨nzlerwa et al., 1982), and ZP subunits (Kubo et al., 1999; Boja et al., 2003;
Darie et al., 2005).
Figure 8. Model of uromodulin shedding and polymerisation. Uromodulin is exclusively expressed by TAL tubular epithelial cells. The protein enters
the secretory pathway and reaches the plasma membrane in a polymerisation-incompetent conformation. This is ensured by the interaction between
two hydrophobic patches within and next to the ZP-C subdomain (Internal Hydrophobic Patch, red circle, and External Hydrophobic Patch, dark green
circle) (Jovine et al., 2004; Schaeffer et al., 2009; Han et al., 2010). Shedding by hepsin at the uromodulin consensus cleavage site (red diamond),
likely occurring at the plasma membrane, releases the hydrophobic interaction, generating polymerisation-competent species that are assembled into
polymeric filaments within the tubular lumen. Pink circles indicate N-terminal EGF-like domains, yellow and green cylinders represent ZP-N and ZP-C
subdomains. The orientation of uromodulin within polymers is hypothetical.
DOI: 10.7554/eLife.08887.025
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Through the identification of hepsin as the protease releasing uromodulin in the urine we discover
the first protease involved in the physiological cleavage of a ZP domain protein, which is a pre-requi-
site for polymerisation of this type of molecules. Notably, Hpn-/- mice were reported to have pro-
found hearing loss likely due to inner ear defects, including a deformed and enlarged tectorial
membrane (Guipponi et al., 2007). This acellular structure, which overlays the organ of Corti, con-
sists of filaments largely composed of ZP domain proteins a- and b-tectorin. The morphology of the
tectorial membrane is similarly altered in mice carrying deafness-causing mutations in a-tectorin
(Legan et al., 2014) that are likely affecting protein secretion (Jovine et al., 2002). These findings,
along with data presented in this manuscript, suggest that inner ear tectorins are also physiological
substrates of hepsin. Moreover, release of glycoprotein-2, a ZP domain protein highly homologous
to uromodulin that is predominantly expressed in pancreas, is mediated by an apical protease sensi-
tive to serine protease inhibitors (Fritz and Lowe, 1996), again suggesting the involvement of hep-
sin. In light of these observations and given the conserved function of the ZP domain and the high
similarity of the consensus cleavage site of ZP domain proteins (Jovine et al., 2004), our results are
likely to be relevant for other members of this protein family.
Materials and methods
Constructs
Uromodulin vectors expressing wild-type HA- or FLAG-tagged protein, soluble mutant S614X and
consensus cleavage site mutant 586RFRS589/586AAAA589 (4Ala mutant) have already been described
(Schaeffer et al., 2009; Schaeffer et al., 2012). A gene encoding the elastase-resistant fragment of
uromodulin (efUmod, lacking residues 27–294) was generated by overlapping PCRs (PCR1: residues
1–26; PCR2: residues 295–640) from wild-type uromodulin cDNA and inserted in pcDNA 3.1(+) (Life
Technologies, Carlsbad, CA) for expression studies in MDCK cells. To generate soluble efUmod for
in vitro cleavage experiments, a DNA fragment encoding uromodulin residues 295–610 was cloned
in pIRES-hrGFP II (Stratagene, Santa Clara, CA). Glycosylation site mutation N513Q and a C-terminal
6His-tag were inserted. The consensus cleavage site mutant 586RFRS589 > 586AYAA589 was also gen-
erated by site-directed mutagenesis (QuikChange Lightning Site-Directed mutagenesis kit, Agilent
Technologies, Santa Clara, CA). Human hepsin and prostasin cDNA (OriGene, Rockville, MD) were
cloned in pcDNA3.1/Zeo(+) (Life Technologies). Myc-tag was inserted at the C-terminus of hepsin by
phosphorylating and annealing the following primers: forward 5’-CCGGTGAGCAAAAGCTGATTTC-
TGAGGAGGATCTGA-3’ and reverse 5’- CCGGTCAGATCCTCCTCAGAAATCAGCTTTTGCTCA -3’.
Catalytically inactive prostasin or hepsin were generated by mutating the serine residue of the cata-
lytic triad (S238A in PRSS8, S353A in HPN) using the QuikChange Lightning Site-Directed mutagene-
sis kit (Agilent Technologies). Primer sequences for generation of all constructs are listed in Table 1.
Human HAI-1 cDNA (Shimomura et al., 1997) cloned in pcDNA3.1(+) was a kind gift of Prof.
Clara Camaschella (San Raffaele Scientific Institute).
Cell lines and culture conditions
Madin-Darby Canine Kidney (MDCK) cells and Human Embryonic Kidney 293 (HEK293) cells were
grown in DMEM supplemented with 10% foetal bovine serum (Euroclone, Pero, Italy), 200 U/ml pen-
icillin, 200 mg/ml streptomycin, and 2 mM glutamine at 37˚C with 5% CO2. They were transfected
using Lipofectamine 2000 (Life Technologies) or Metafectene Pro (Biontex, Munich, Germany)
respectively. Selection of stably transfected MDCK cells with G418 (Life Technologies) was started
24 hr after transfection and was pursued for 1–2 weeks. To obtain electrically tight monolayers
(>100 W cm-2), MDCK cells were grown on filters (Corning, Corning, NY) for 4 days. Uromodulin
secretion in MDCK or HEK293 cells was analysed after 16 hr incubation in Optimem (Life
Technologies).
Cellular treatment with protease inhibitors
MDCK cells stably expressing uromodulin were grown on coverslip. After 24 h, the medium was
replaced with Optimem supplemented with 0.1% protease inhibitor cocktail (PIC) (P8340, Sigma-
Aldrich, Saint Louis, MO), 0.1% DMSO, 0.1 mM AEBSF, 0.08 mM aprotinin, 1.4 mM E64, 4 mM
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bestatin, 2 mM leupeptin and 1.5 mM pepstatin A (Sigma-Aldrich). Immunofluorescence analysis was
performed after 24 hr of treatment.
Silencing of hepsin and prostasin expression
Sfold (http://sfold.wadsworth.org/cgi-bin/index.pl) and siDESIGN center (http://www.thermoscienti-
ficbio.com/design-center/) were used to identify siRNAs targeting canine hepsin and prostasin.
Selected oligos (sense sequence) are listed in Table 2. Oligonucleotides for shRNA strategy were
designed combining the siRNA sequence (sense) followed by a loop (sequence 5’-3’: TTCAAGAGA),
the reverse complement of the siRNA sequence (antisense) and RNA polymerase III terminator
(sequence 5’-3’: TTTTTTGGAA). Oligos were phosphorylated, annealed and inserted in pENTR/
pTER+, a gift from Eric Campeau (plasmid # 17453, Addgene, Cambridge, MA) (Campeau et al.,
2009). MDCK cells stably expressing uromodulin were co-transfected with pENTR/pTER+ vector
and EGFP-expressing vector pcDNA3x(+)MyEGFP (Life Technologies). Cells were collected 24 hr
after transfection and sorted using MoFlo sorter (Beckman Coulter, Brea, CA). Recovered EGFP-pos-
itive cells were maintained in culture for 48 hr.
In silico analyses
A list of human serine proteases was derived from the MEROPS database (http://merops.sanger.ac.
uk/). The expression profile of these enzymes in MDCK and HEK293 cells was analysed in Gene
Expression Omnibus DataSets database (http://www.ncbi.nlm.nih.gov/gds) using baseline replicates
of the following series: GSD3267 (Hellman et al., 2008), GSE20193 (Sharma et al., 2010),
GSE18739 (Abd Alla et al., 2010), GSE15575 (Abd Alla et al., 2009), GSE1309 (Zagranich-
naya, 2005), GSE1364 (Jack et al., 2006), GSE51118 and GDS1852 (Elkon et al., 2005). Membrane
association of the enzymes was derived from Uniprot database (http://www.uniprot.org/). Protease
expression in TAL cells was analysed by including series GSE13672 (Yu et al., 2009) and GSE25223
(Cheval et al., 2011).
Mouse lines
Wild-type, Hpn-/- (Wu et al., 1998), Prss8lox/lox (Rubera et al., 2002) and Prss8-/- animals are in
C57BL/6J background. Adult nephron-specific Prss8-deficient (Prss8-/-) mice were obtained by inter-
breeding of Prss8lox/lox with Pax8-rtTA/LC1tg/+ (Traykova-Brauch et al., 2008). Briefly, 28 day-old
Prss8-/- and Prss8lox/lox (control) littermates were treated with doxycycline (2 mg/ml) in 2% sucrose in
Table 1. Primers (5’-3’) used to generate UMOD and protease constructs.
efUMOD-PCR1
T7: TAATACGACTCACTATAGGG
Reverse: ACACGTCCCCTCCACGTGGTGATGGTGATGATGAC
efUMOD-PCR2
Forward: CATCACCATCACCACGTGGAGGGGACGTGTGAGGA
BGHrev: TAGAAGGCACAGTCGAGG
efUMOD_sol
Forward: GGACAGATCTACGTCGACGGGACGTGTGAGGAGTGCAG
Reverse: CCGGAATTCCTAGTGATGATGGTGATGATGCTGGACACCTTTCCGTGTG
efUMOD_AYAA
Forward: CCTACCTGCTCTGGGACCGCATACGCAGCTGGGAGTGTCATAGATCAATCCC
Reverse: GGGATTGATCTATGACACTCCCAGCTGCGTATGCGGTCCCAGAGCAGGTAGG
efUMOD_N513Q
Forward: CACCCAGTAGCCAGGCCACGGACCCCC
Reverse: GGGGGTCCGTGGCCTGGCTACTGGGTG
PRSS8_S238A
Forward: GCCAGGGTGACGCTGGGGGCCCA
Reverse: TGGGCCCCCAGCGTCACCCTGGC
HPN_S353A
Forward: CTGCCAGGGCGACGCCGGTGGTCCCTTT
Reverse: AAAGGGACCACCGGCGTCGCCCTGGCAG
DOI: 10.7554/eLife.08887.026
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drinking water for 15 days. Genotyping by PCR was performed as previously described
(Malsure et al., 2014; Ronzaud et al., 2013).
All animal procedures were carried out at the Lerner Research Institute, Cleveland Clinic, USA; at
the University of Lausanne, Lausanne, Switzerland and at the University of Zurich, Zurich, Switzerland,
according to protocols approved by the Institutional Animal Care and Use Committee at the Lerner
Research Institute and by the Swiss Cantonal Veterinary Authority.
Protein extracts, immunoprecipitation and Western blot analysis
MDCK and HEK293 cells, or mouse tissues were solubilised in lysis buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 60 mM octyl-b-D-glucopyranoside and 0.1% PIC). Cell-conditioned medium or urinary
proteins were precipitated with acetone and resuspended in PBS. When needed, samples were N-
deglycosylated with PNGase F (New England Biolabs, Ipswich, MA). Lysates were quantified with the
Bio-Rad Protein Assay (Bio-Rad, Hercules, CA).
Precleared lysates of HEK293 cells (300 mg) were loaded onto protein G Sepharose beads
(Sigma-Aldrich) pre-conjugated with 2 mg of mouse anti-HA antibody (Covance, Princeton, NJ) and
incubated 16 hr at 4˚C. After washes in PBS-triton 0.5%, beads were resuspended in Laemmli Buffer.
Protein lysates, immunoprecipitated proteins, urinary or secreted proteins were separated on
reducing 8% SDS-PAGE gel and transferred onto nitrocellulose membrane (GE Healthcare, Little
Chalfont, United Kingdom). Western blotting (WB) was performed following standard protocols.
Quantification was performed using the gel analysis option of ImageJ software (http://rsbweb.nih.
gov/ij/) (Schneider et al., 2012).
Collection and processing of plasma, urine samples and renal tissues
Kidneys for immunofluorescence or microdissection of nephron segments were collected from 2–3-
month-old male wild-type control mice. Nephron segment microdissection was performed and vali-
dated as previously described (Glaudemans et al., 2014). Plasma, urine and kidneys from wild-type
and Hpn-/- mice were collected from 2.5-month-old male mice. Urine and kidneys from Prss8lox/lox
and Prss8-/- were collected from 1.5-month-old mice.
Animals were housed in a light- and temperature-controlled room with ad libitum access to tap
water and standard chow. Urine collections (16 h) were obtained at baseline using individual meta-
bolic cages, after appropriate training. Urinary creatinine quantification was performed using creati-
nine assay kit (Cayman Chemical, Ann Arbor, MI). Blood samples were collected from the vena cava.
Serum creatinine levels were measured by Consolidated Veterinary Diagnostics (West Sacramento,
CA). Polymerisation assay on urinary samples was performed as previously described (Jovine et al.,
2002). Supernatants were precipitated with acetone, while pellets were solubilised in Laemmli
Buffer.
Immunofluorescence analysis
Immunofluorescence (IF) of cells grown on coverslip was carried out as previously described
(Schaeffer et al., 2009). Cells grown on filters were fixed 20 min in 4% paraformaldehyde (VWR
International, Radnor, PA) and permeabilised 15 min at 37˚C with 0.7% gelatin and 0.016% saponin.
Cells were incubated for 1 hr at 37˚C with primary antibody and subsequently with the appropriate
AlexaFluor-labeled secondary antibody (Life Technologies). Nuclei were stained with 4’,6-diamidino-
2-phenylindole (DAPI, Life Technologies) and slides were mounted using fluorescent mounting
Table 2. Oligonucleotide sequences used to generate shRNAs.
Target gene Target position from ATG codon siRNA oligo (5’-3’)
HPN_siRNA#1 122-140 CCTTCCTACTCAAGAGTGA
HPN_siRNA#2 1195-1213 TGGATCTTCCAGGCCATAA
PRSS8_siRNA#1 258-276 GAAGGAAGACTATGAGGTA
PRSS8_siRNA#2 593-611 TGTACAACATCAACGCTAA
Control siRNA NA TAGTGAGATTCGTTAAGAT
DOI: 10.7554/eLife.08887.027
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medium (Dako, Agilent Technologies). Slides were visualised under a DM 5000B fluorescence
upright microscope (Leica, Wetzlar, Germany) or under an UltraVIEW ERS spinning disk confocal
microscope (PerkinElmer, Waltham, MA). Quantification of mean polymeric area was performed
using ImageJ software, as previously described (Schaeffer et al., 2012). Polymers were quantified
on 5–9 independent images for each condition taken at 10x magnification. Cell and polymer recon-
structions were carried out by collecting stacks of consecutive confocal images at 0.5 mm intervals.
Extended focus 2D images were obtained by using Volocity 3D Image Analysis Software version 6.3
(PerkinElmer, Waltham, MA).
Kidneys for immunofluorescence were collected from mice anaesthetised and perfused with 3%
paraformaldehyde and snap-frozen in liquid propane. Kidney sections (4–5 mm thick) were reacti-
vated in PBS for 30 min and blocked with 10% goat serum for 30 min. They were incubated over-
night at 4˚C with with relevant primary antibodies (anti-hepsin, -prostasin or –uromodulin). For co-
localisation with uromodulin, sections were blocked again for 30 min and incubated for 2 hr with the
anti-uromodulin primary antibody. Slides were incubated with the appropriate AlexaFluor-labelled
secondary antibody diluted in PBS containing DAPI and mounted with Prolong Gold anti-fade
reagent (Invitrogen, Life Technologies). Slides were visualised with a Leica SP5 Confocal microscope.
Antibodies
We used the following primary antibodies: mouse anti-HA (MMS-101P, 1:1000 for WB and 1:500 for
IF, Covance), rabbit anti-FLAG (F7425, 1:500 for IF, Sigma-Aldrich), goat anti-Myc (NB600-335,
1:500 for IF, Novus Biologicals, Littleton, CO), sheep anti-uromodulin (T0850, 1:1000 for WB, US Bio-
logical, Salem, MA), sheep anti-uromodulin (K90071C, 1:200 for IF, Meridian Life Science, Cincinnati,
OH), goat anti-uromodulin (55140, 1:1000 for WB and 1:500 for IF, MP Biomedicals, Santa Ana, CA),
rabbit anti-hepsin (100022, 1:1000 for WB and 1:50 for IF, Cayman Chemical), sheep anti-prostasin
(AF4599, 1:1000 for WB and 1:200 for IF, R&D System, Minneapolis, MN), rabbit anti-prostasin (kind
gift of Prof. Carl Chai, University of Central Florida College of Medicine, FL; 1:200 for IF)
(Chen, 2006), rabbit anti-HAI-1 (H-180, 1:1000 for WB, Santa Cruz Biotechnology, Santa Cruz, CA),
rabbit anti-PDI (H-160, 1:1000 for WB, Santa Cruz Biotechnology), mouse anti-E-cadherin (610182,
1:500 for IF, BD Biosciences, San Jose, CA), mouse anti-KDEL (ADI-SPA-827-D, 1:500, Enzo Life Sci-
ences, Farmingdale, NY), mouse anti-GAPDH (6C5, 1:5000 for WB, Santa Cruz Biotechnology),
mouse anti-b actin (A2228, 1:16000 for WB, Sigma-Aldrich), mouse anti-a tubulin (SC-8035, 1:1000
for WB, Santa Cruz Biotechnology) and mouse anti-5His (34660, 1:1000 for WB, Qiagen, Venlo, The
Netherlands).
RNA extraction, RT-PCR and Real-Time qPCR
Total RNA was extracted from confluent cells or from mouse kidneys using TRIzol reagent (Life Tech-
nologies) and reverse-transcribed using iScript kit (Bio-Rad). Expression of target genes was analysed
by RT-PCR (@Taq, Euroclone) or by Real-Time qPCR on LightCycler 480 (Roche, Basel, Switzerland)
using qPCR Core kit for SYBR Assay (Eurogentec, Seraing, Belgium).
Hpn and Prss8 expression in microdissected nephron segments were assessed by Real-Time
qPCR with a CFX96TM Real-Time PCR Detection System (Bio-Rad) using iQTM SYBR Green Supermix
Table 3. Primers used for gene expression analysis (RT-PCR).
Gene PCR product length Primer (5’-3’)
HPN
(Dog / Human)
353 bp Forward: GCTGCGAGGAGATGGGCTTC
Reverse: CGGGAAGCAGTGGGCGGCTG
PRSS8
(Dog / Human)
547 bp Forward: CCTGGCAGGTCAGCATCACC
Reverse: CCAGAGTCACCCTGGCAGGC
GAPDH
(Human)
314 bp Forward: CCACCCAGAAGACTGTGGAT
Reverse: GTTGAAGTCAGAGGAGACCACC
GAPDH
(Dog)
289 bp Forward: CTCTGGGAAGATGTGGCGTGAC
Reverse: GTTGAAGTCACAGGAGACCACC
DOI: 10.7554/eLife.08887.028
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(Bio-Rad). The relative mRNA expression of genes of interest was calculated following the DDCt
method (Pfaffl, 2001). Primer sequences are listed in Table 3 and Table 4.
Statistical analysis
Comparisons between groups were performed using two-tailed unpaired t-test or Mann-Whitney
test. We expressed continuous measures as the mean ± the standard deviation (s.d.); averages of
measurements as the mean ± the standard error of the mean (s.e.m.). We set significance level to
p<0.05.
Purification of efUmod and in vitro cleavage
Chinese Hamster Ovary (CHO) DG44 cells were grown in a-MEM medium supplemented with 10%
foetal bovine serum (Life Technologies) and stably transfected with pIRES-hrGFP_efUMOD. Stable
cells were cultured in HyQ SFM4CHO-utility medium (Thermo Scientific, Waltham, MA). efUmod
secreted by CHO cells was purified by batch IMAC with Ni-NTA Superflow (Qiagen), followed by
SEC using a HiLoad 26/60 Superdex 200/HiPrep 26/60 Sephacryl 200 double column system (GE
Healthcare) equilibrated against 10 mM Tris-HCl pH 8.0 at 4˚C, 50 mM NaCl, and concentration.
Recombinant efUmod (25 ng/ml) was incubated with human serine proteases hepsin (Enzo Life Scien-
ces, Farmingdale, NY) or prostasin (R&D System) in 50 mM Tris, 20 mM NaCl, pH 7.8 at 37˚C for
10 hr. Picomolar ratio between protease and efUmod was 1:100 for hepsin and 1:5 for prostasin.
Electron microscopy of uromodulin filaments secreted by MDCK cells
MDCK cell conditioned media were centrifuged 30 min at 18,000 x g at 4˚C, resuspended in ultra-
pure water and applied to glow-discharged 400 mesh copper grids with a carbon support film. After
5 min the grids were washed with ultrapure water for 2 min and then negatively stained with 2% ura-
nyl acetate. Samples were analysed using a CM120 electron microscope (Philips, Eindhoven, The
Netherlands) equipped with a LaB6 electron source. Images were recorded on Kodak SO163 elec-
tron film (Eastman Kodak, Rochester, NY) and digitised using an Epson Perfection 4990 PHOTO flat-
bed scanner (Epson, Suwa, Japan).
Mass spectrometric analysis of uromodulin secreted by MDCK cells
MDCK cell-conditioned media were centrifuged at 3,000 x g for 5 min at 4˚C. Supernatants were
concentrated using Amicon Ultra-3K (Millipore, Billerica, MA) at 4,000 x g at 4˚C and depleted of
the most abundant proteins using IgY-12 columns (Genway, San Diego, CA). Proteins were precipi-
tated with 60% TCA (trichloroacetic acid, Sigma-Aldrich) for 1 hr at -20˚C and washed with 90% ace-
tone. Two hundred mg were diluted in 130 ml of a buffer containing 5 M urea (Sigma-Aldrich), 2 M
thiourea (Sigma-Aldrich), 2% CHAPS (Sigma-Aldrich), 2% Zwittergent (GE Healthcare), 100 mM
Table 4. Primers used for gene expression analysis (Real-Time qPCR).
Gene PCR product length Primer (5’-3’)
HPN
(Dog)
164 bp Forward: TGGTCCACCTGTCCAGCCCC
Reverse: GACTCGGGCCTCCTGGAGCA
Hpn
(Mouse)
152 bp Forward: CTGACTGCTGCACATTGCTT
Reverse: GGGTCTCGAAAGGGAAGGTA
PRSS8
(Dog)
156 bp Forward: TCCGGACTTGCCTTCTGCGGT
Reverse: AGCTGAGAGCACCCACTGCTCA
GAPDH
(Dog)
289 bp Forward: CTCTGGGAAGATGTGGCGTGAC
Reverse: GTTGAAGTCACAGGAGACCACC
Prss8
(Mouse)
147bp Forward: ATCACCCACTCAAGCTACCG
Reverse: AGTACAGTGAAGGCCGTTGG
Umod
(Mouse)
207 bp Forward: ATGGACCAGTCCTGTCCTG
Reverse: CCGTCTCGCTTCTGTTGAGT
Hprt1
(Mouse)
162 bp Forward: ACATTGTGGCCCTCTGTGTG
Reverse: TTATGTCCCCCGTTGACTGA
DOI: 10.7554/eLife.08887.029
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DeStreak (GE Healthcare) and 0.5% IPG buffer pH 3–10 NL (GE Healthcare) and loaded on Immobi-
line Dry strip pH 3–10 NL, 7 cm (GE Healthcare, total focusing run 50,000 Vh). IPG strips were
sequentially reduced and alkylated prior to the second dimension electrophoresis. SDS-PAGE 8%
gels were Coomassie stained and spots of interest were excised and in-gel digested as previously
reported (Shevchenko et al., 1996). For nLC-MS/MS analysis, peptide mixtures were acidified up to
1% formic acid and analysed on an API QStar PULSAR (AB-Sciex, Framingham, MA) mass spectrom-
eter as previously reported (Magagnotti et al., 2013). All MS/MS samples were analysed using
MASCOT engine (version 2.2.07, Matrix Science, London, United Kingdom) and X!Tandem (within
Scaffold software, v.3.6.4, Proteome Software, Portland, OR) to search the UniProt_CP_Human
2013_05 database. Peptide mass tolerance of 200 ppm and 0.6 Da for precursor and fragment ions
were selected respectively. Searches were performed with: semi-Lys-C or semi-Asp-N specificity; car-
bamidomethylation of cysteine as fixed modification and oxidation of methionine as variable modifi-
cation. Scaffold was used to validate MS/MS based peptide and protein identifications with protein
thresholds set to 99%, 2 peptides minimum and peptide thresholds set to 95% minimum.
Mass spectrometric analysis of urinary uromodulin
Uromodulin was purified from 1 ml of mouse urinary samples as previously described
(Santambrogio et al., 2008). PNGase F-treated and alkylated samples were separated on 8% SDS–
PAGE gel. Bands of interests were excised from Coomassie stained gels, reduced, alkylated and
finally digested overnight with trypsin or Asp-N (Roche) (Santambrogio et al., 2008). After acidifica-
tion, peptide mixtures were concentrated and desalted on homemade Stagetips mC18
(Rappsilber et al., 2007) and injected in a capillary chromatographic system (EasyLC, Proxeon Bio-
systems, Thermo Scientific). Peptide separations occurred on a homemade fused silica capillary col-
umn (75 mm i.d.  25 cm), packed with 3 mm ReproSil-Pur C18-AQ (Dr. Maisch, Ammerbuch-
Entringen, Germany). A gradient of eluents A (H2O with 2% acetonitrile, 0.5% acetic acid) and B
(80% acetonitrile with 0.5% acetic acid) was used to achieve separation, from 4% to 70% B (in
65 min, 0.15 mL/min flow rate). The LC system was connected to an LTQ-Orbitrap mass spectrome-
ter (Thermo Scientific) equipped with a nanoelectrospray ion source (Proxeon Biosystems). MS and
MS/MS spectra were acquired selecting the ten most intense ions per survey spectrum acquired in
the orbitrap from m/z 300–1750 with 60,000 resolution. Target ions selected for the MS/MS were
fragmented in the ion trap and dynamically excluded for 120 sec. Target values were 1,000,000 for
survey scan and 100,000 for MS/MS scan. MS/MS spectra were converted into peaklist (.msm files)
and analysed using MASCOT and Scaffold searching against the UniProt_CP_Mus 2012_10 data-
base. Searches were performed with: semi-Asp-N or semi-trypsin specificity; parent ion tolerance of
5.0 ppm and fragment ion mass tolerance of 0.60 Da; N-ethylmaleimide or carbamidomethyl of cys-
teine as fixed modifications; oxidation of methionine, asparagine deamidation and acetylation of the
N-terminus of proteins as variable modifications.
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